Ocular hypertension

3 trials MedDRA PT
3 Registered trials
0 Recruiting
2 Unique sponsors
3 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
S Ophthalmology/ENT (ATC S) 1
Mechanism of action (INN-stem analysis)
Beta-blocker 2 substances
Unknown / small molecule 1 substance
Phase III: 3

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

3 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    BIMATOPROST
    2023-504601-36-00 4 countries 2019 n=28
    Ended
  • AbbVie Deutschland GmbH & Co. KG Commercial
    BIMATOPROST; TIMOLOL MALEATE
    2024-519595-87-00 1 country 2015 n=3
    Ended
  • Becro (Cyprus) Limited Commercial
    TIMOLOL MALEATE, BRIMONIDINE TARTRATE
    2023-507285-24-00 1 country 2024 n=180
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
AbbVie Deutschland GmbH & Co. KG Commercial 2 Phase III 0
Becro (Cyprus) Limited Commercial 1 Phase III 0
New trials by year
2019
1
2024
1
← All indication landscapes